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Abstract
Interleukin-6 (IL-6) is a multifunctional cytokine regulating humoral and cellular responses and playing a central role
in inflammation and tissue injury. Its effects are mediated through interaction with its receptor complex, IL-6Rb
(also known as gp130). It plays an important role in the pathogenesis of coronary artery disease and large quanti-
ties of IL-6 are found in human atherosclerotic plaques. IL-6 levels positively correlate with higher all-cause mortal-
ity, unstable angina, left ventricular dysfunction, propensity to diabetes and its complications, hypertension, obesity
and several types of cancer. IL-6 levels augmentation demonstrates a remarkable parallel with another biomarkers
reflecting harmful processes, like tumor necrosis factor alpha, interleukins 8 and 18, YKL-40, C reactive protein and
resistin. Due to these facts, IL-6 was classified as a noxious interleukin. Nonetheless, there are several facts that chal-
lenge this usually accepted point of view. Since IL-6 has also anti-inflammatory activity, it seems reasonable to
assume that favorable aspects exist. These aspects are two: 1. protection against bacterial infections, inactivating
proinflammatory mediators, mitigating the course of septic shock and inducing the production of cortisol; and 2.
influence on insulin sensitivity during exercise; this aspect is even more important. During exercise IL-6 is synthe-
sized and released by muscles, with enhanced insulin action immediately at early recovery. Skeletal muscle may be
considered as an endocrine organ; contracting muscles produce IL-6 and release it into the blood exerting its
effects on other organs. The increase in circulating levels of IL-6 after exercise is consistent and proportional to
exercise duration, intensity, muscle mass involved and endurance capacity. Thus, the fascinating possibility that the
plenteous beneficial health effects of exercise could be ultimately mediated by IL-6 merits further elucidation. Inter-
leukins were termed “good” or “bad”, probably due to a tendency to see things in black and white, with no gray
area in between. Calling IL-6 “a molecule with both beneficial and destructive potentials” would be a more equita-
ble approach. In the literary creatures of Dr. Jekyll and Mr. Hyde, a good and an evil personality are found in the
same individual. IL-6 playing the role of Dr. Jekyll is emerging; the time for IL-6 reappraisal is coming.
Evidence continues to pile during the last two decades
regarding the clinical relevance of laboratory predictors of
pathophysiological events. These predictors are molecules,
usually in the picogram (pg) range, called biomarkers.
New and more specific biomarkers are currently isolated
employing sophisticated bioinformatics approaches [1,2].
A biomarker is defined as a biochemical characteristic that
may be objectively quantified and evaluated as an indicator
of normal biological processes, pathogenic events, or
responses to pharmacological or other therapeutic inter-
ventions. Thus, biomarkers are classified into 3 different
types: Type 0, which estimates the emergence or advance
of a disease, Type 1, which measures responses to
therapeutic interventions, and Type 2, which may be
employed as surrogate clinical endpoints [3,4].
In this context, interleukin-6 (IL-6) has gained a lead-
ing role. Its popularity is rooted on the fact that it can
be defined either as a Type 0, 1 or 2 biomarker, depend-
ing on the given clinical setting. Thus, overlapping the 3
types of biomarkers, IL-6 attained a wide use in experi-
mental and clinical studies. IL-6 is a multifunctional
cytokine. It regulates humoral and cellular responses
and plays a central role in inflammation and tissue
injury. Its effects are mediated through interaction with
its receptor complex, IL-6Rb (also known as gp130) as a
signaling subunit. This cytokine plays a very important
role in the pathogenesis of coronary artery disease
(CAD) [5]. Large quantities of IL-6 are found in human
atherosclerotic plaques [6]. IL-6 levels are associated to
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elevated in patients with unstable angina compared with
those with stable disease [8]. Moreover, patients with
persistently elevated IL-6 levels demonstrate a worse in-
hospital outcome following admission with unstable
angina [9,10], as well as left ventricular diastolic dys-
function in both clinical trials [11] and experimental
animal models [12]. We have also shown that in CAD
patients with angina pectoris and/or healed myocardial
infarction (MI), a significantly higher risk for future car-
diac morbility and mortality was found in the upper IL-
6 quintile (odds ratio, 3.44; 95% CI 1.57-8.13) after a
mean follow-up period of 6.3 years [13]. IL-6 is also ele-
vated in experimental MI models [14].
Additionally, IL-6 seems to embody a negative role in
both main types of diabetes. After adjustment for age,
gender, body mass index, waist-to-hip ratio, sports,
smoking, alcohol consumption and other variables, IL-6
emerges as an independent early predictor of type 2 dia-
betes mellitus (T2DM), preceding its clinical onset [15].
Type 1 diabetes mellitus (T1DM) young patients - even
in good glycemic control - show higher levels of IL-6
and fibrinogen than controls [16]. It has been shown
that postmenopausal women with T1DM present higher
serum bioactive IL-6 levels than matched healthy con-
trols [17] and that subjects with diabetic foot show
higher IL-6 values in comparison with T2DM patients
without diabetic foot complication [18]. Additionally,
IL-6 polymorphism seems to be a genetic susceptibility
factor for the progression of diabetic nephropathy
[19,20].
Besides its roles in the cardiovascular system and in
regulation of glucose metabolism, IL-6 ubiquity is aston-
ishing. Secreted by several types of cells, mainly macro-
phagues and T cells, the pleiotropic IL-6 is related to
both immunoregulation and nonimmune physiological
traits in most cell types and tissues outside the immune
system [21]. Expressing a state of low grade chronic
inflammation, IL-6 augmented levels have been reported
to be directly related to the severity of sepsis [22],
hypertension [23], poor survival among head and neck
cancer patients [24], development of hairy cell leukemia
[25], increased breast cancer risk in premenopausal
women [26], intensity of inflammatory responses
[27-29], obesity [30,31], increased insulin resistance
[23,32-34], etc. In addition, IL-6 levels augmentation
demonstrates a remarkable parallel with another bio-
markers reflecting harmful processes, like tumor necro-
sis factor alpha (TNFa) [11,35], interleukins 8 and 18
[5,36], YKL-40 [37], C reactive protein (CRP) [38-40],
resistin [41], etc. A comprehensive review of IL-6
numerous and complex biological effects is beyond the
scope of this article.
Based on the above facts, IL-6 appears to be involved
in a long series of deleterious actions, and it was classi-
fied as a noxious or “bad” interleukin [5,42]. Nonethe-
less, there are several facts that challenge this usually
accepted point of view. A reconsideration is needed, as
detailed hereinafter.
Curtails of interleukin research
The concept of IL-6 being a damaging factor has growth
mainly on the basis of statistical correlations in clinical
studies, in vitro cell culture studies at supraphysiological
levels of IL-6 and animal models employing mice [43].
Several important points should be taken into consid-
eration when performing interleukin research: 1)
increased levels of a given IL, presenting statistical corre-
lation with disease, does not necessarily imply causation;
2) these compounds are characterized by substantial
redundancy in that different interleukins have similar
and overlapping functions; 3) interleukins may stimulate
secretion of other interleukins, enhancing or inhibiting
each other; 4) interleukins possess ‘paradoxical’ effects,
expressed as protective properties regarding a given sys-
tem, whereas they may damage another system, and 5)
protective or noxious effects of a given interleukin may
be concentration-dependent [5,42].
These general rules also pertain specifically to IL-6.
Thus, studies “blaming” IL-6 based on statistical ana-
lyses or cell culture at high IL-6 concentrations could
be partially biased by the mentioned intrinsic drawbacks.
Regarding mice studies, it should be pointed out that
comparative genomics research demonstrated that
mouse and human IL-6 share only 42% aminoacid
sequence identity [21]; hence, in this particular case
extrapolation of mice findings to humans requires
extreme caution.
Another problem that jeopardizes IL-6 research and
may intricate IL-6 use as a bedside laboratory tool is the
variability of its values. The established normal values
are 1 pg/ml [44,45], but they increase at several settings
like a single high fat meal [46] physical activity [47],
normal menstrual cycle [48], acute hyperglycemia [49]
or during and after surgery [50]. Pregnancy represents a
good example of this inconsistency: median values of
129 pg/ml were registered at delivery, decreasing to 58
pg/ml immediately afterward [51]. Moreover, during
sepsis IL-6 may reach even much more higher values
[52].
Beneficial effects
Besides its proinflammatory properties, IL-6 and IL-6-
regulated acute-phase proteins show also anti-inflamma-
tory activity [53,54]. Then, it seems reasonable to
assume that IL-6 is not such a bad guy. We will briefly
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bacterial infections and its particular influence on insu-
lin sensitivity during exercise.
The protective IL-6 effects in infections were
described almost three decades ago. Sometimes the
interpretation of the results may be controversial since
it is debatable whether in sepsis IL-6 represents an
inflammation marker and/or a mediator of immune
defense responses. Despite discordant results, some
issues seem to be rather consistent. In neonatal mouse
models of Group B streptococcal disease IL-6 decreases
TNFa production, as well as the expression of TNF
receptors in macrophages [55,56]; exogenous adminis-
tration of IL-6 improved survival and complete inhibi-
tion of IL-6 resulted in a more rapid mortality [56]. IL-6
inactivates proinflammatory mediators and mitigates the
course of septic shock [57]; it also induces the produc-
tion of adrenocorticotropin and, in turn, cortisol, which
is a potent anti-inflammatory hormone [58]. In mice
infected with the intracellular pathogen Listeria mono-
cytogenes, recombinant mouse IL-6 injected intraperito-
neally before infection protected mice in a
dose-dependent manner, resulting in decreased bacterial
numbers in the spleen and liver; IL-6 played a role in
early priming of the immune response to infection [59].
A n y w a y ,i tm u s tb ep o i n t e do u tt h a tt h e s ee n c o u r a g i n g
results are partially overshadowed by the lack of con-
trolled clinical studies.
The second aspect - insulin metabolism during exer-
cise - is even more important. The overwhelming in
vitro findings linking IL-6 to increased insulin resistance
may lack clinical relevance as in vivo human studies
demonstrate that neither splanchnic glucose output nor
isotopic tracer determined endogenous glucose produc-
tion are increased by acute infusion of recombinant
human IL-6 (rhIL-6) [43,60]. During exercise IL-6 is
synthesized and released by skeletal muscle [61] and its
plasma concentrations may be increased as much as
100-fold [47] - in parallel with the intensity and dura-
tion of exercise - this represents a far greater increase
than that of any other cytokine that has been measured
[61]. In this context, it was shown that IL-6 is rapidly
released into the circulation following exercise [47], with
enhanced insulin action immediately at early recovery.
The improved insulin sensitivity is probably mediated by
adenosine monophosphate-activated protein kinase
(AMPK) [62,63].
In addition, rhIL-6 infusion during a hyperinsulinemic-
euglycemic clamp in healthy humans does not effect the
insulin-mediated suppression of endogenous glucose pro-
duction, while increasing glucose infusion rate [64]. Exer-
cise-induced improvement of insulin sensitivity is mainly a
local phenomenon, occurring primarily in the exercised,
rather than the rested, muscles. This was confirmed from
experiments using both rodent and human models where
muscles in only one limb have performed work prior to
evaluation of insulin action in both limbs [63,65]. In both
types of trials the prior exercised leg takes up glucose to a
far greater extent and with enhanced insulin sensitivity
compared with the rested leg. The changes may be of
small magnitude, but over time they become important at
the whole body [63].
It has been demonstrated that signaling pathways from
contracting muscles to other organs are not solely
mediated by the nervous system, since electrical stimula-
tion of paralyzed muscles in spinal-cord-injured patients
induces many of the same physiological changes as in
neurological healthy individuals [66]. Therefore, it was
clear that some humoral factor must exist. IL-6 fulfils
the criteria of being that factor, via AMPK activation
[47,54,64].
Concluding comment
One of the more important proofs concerning the cru-
cial importance of IL-6 emerges from an experimental
rodent genetic model dated 3 quinquenniums ago.
A targeted disruption of the IL-6 receptor complex
gp130 was performed. Embryos homozygous for the
gp130 mutation showed hypoplastic ventricular myocar-
dium, reduced numbers of pluripotential cells - mainly
hematopoietic progenitors - anemia and several addi-
tional abnormalities. The results indicate that gp130
plays a crucial role in myocardial development and
hematopoiesis during embryogenesis [67].
Undesirable effects of IL-6 paharmacological blocking
maybe reflected also in a clinical routine setting. In
recent years, tocilizumab, a humanized anti-IL-6-recep-
tor monoclonal antibody, was developed and success-
fully used for the treatment of rheumatoid arthritis and
juvenile idiopathic arthritis [68]. Common adverse
events of the therapy were gastrointestinal, nasopharyn-
geal, and upper-respiratory-tract infections. More ser-
ious adverse events - an anaphylactoid reaction and a
gastrointestinal hemorrhage - were also reported [69].
These events are probably related to IL-6-receptor
inhibition.
The key IL-6 positive action is its relationship with
physical activity via enhancement of insulin-stimulated
glucose disposal in humans in vivo [64,70]. Skeletal
m u s c l em a yt h e nb ec o n s i d e r e da san e w l yd i s c o v e r e d
endocrine organ; contracting muscles produce IL-6 and
release it into the blood [43,47,71] exerting its effects on
other organs in a hormone-like fashion. The increase in
circulating levels of IL-6 after exercise is a consistent
finding, proportional to exercise duration, intensity of
effort, the muscle mass involved in the mechanical work
and the endurance capacity [71]. Thus, the fascinating
possibility that the plenteous beneficial health effects of
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further elucidation.
Interleukins were termed or classified as “good” or
“bad” [5,13,72], probably due to a tendency to see things
in black and white, with no gray area in between. Call-
ing IL-6 “a molecule with both beneficial and destructive
potentials” [73] would be a more equitable approach. In
the literary creatures of Dr. Jekyll and Mr. Hyde, a good
and an evil personality are found in the same individual
[74]. IL-6 playing the role of Dr. Jekyll is emerging; the
time for IL-6 reappraisal is coming.
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